GlassScriptPhysician profile
Richard Klump
NPI 1114971512
$1,566.83
in general payments reported to CMS, 2019-2025
31 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $41.10 · 2021: $303 · 2022: $262 · 2023: $248 · 2024: $235 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.20 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $215.93 | 2019-2021 | |
| Olympus America INC. | $169.94 | 2022-2023 | Itind System |
| Sumitomo Pharma America, INC. | $168.34 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $101.38 | 2019-2025 | Erleada, Akeega, Balversa |
| 180 Medical, INC. | $91.43 | 2019-2021 | |
| Myovant Sciences INC. | $80.18 | 2021-2022 | |
| Urogen Pharma, INC. | $65.56 | 2021-2024 | |
| Genzyme Corporation | $62.25 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $53.97 | 2019-2023 | Provenge |
| Coloplast Corp | $51.09 | 2019-2021 | |
| Boston Scientific Corporation | $48.86 | 2019-2025 | Lithovue |
| Abbvie INC. | $45.34 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $43.88 | 2020-2023 | Xiaflex, Aveed |
| Teleflex LLC | $42.00 | 2024 | Urolift |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $34.02 | 2025 | |
| Accord Healthcare, INC. | $31.98 | 2022-2024 | |
| Convatec INC. | $26.72 | 2023 | |
| Medtronic USA, INC. | $26.37 | 2019 | |
| Urovant Sciences INC | $23.99 | 2021 | |
| Trevena, INC. | $20.60 | 2024 | Olinvyk |
| Blue Earth Diagnostics | $19.07 | 2023 | |
| Procept Biorobotics Corporation | $16.47 | 2024 | Aquabeam System |
| Amgen INC. | $14.47 | 2019 | |
| Pfizer INC. | $14.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.91 | 2019 | |
| Medtronic, INC. | $13.54 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $12.92 | 2023 | Welireg, Keytruda, Lynparza |
| Antares Pharma, INC. | $12.60 | 2020 | |
| Travere Therapeutics, INC. | $10.56 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$990.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Klump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.